Warning! GuruFocus detected
7 Severe warning signs
with 6UI.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Arecor Therapeutics PLC
ISIN : GB00BMWLM973
Share Class Description:
FRA:6UI: Ordinary SharesDescription
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, Germany, Italy, the Rest of Europe, the USA, and India, out of which the majority is from the UK.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.09 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.62 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.7 | |||||
| 3-Year EBITDA Growth Rate | -32.4 | |||||
| 3-Year EPS without NRI Growth Rate | -41.4 | |||||
| 3-Year FCF Growth Rate | -41.6 | |||||
| 3-Year Book Growth Rate | 123.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 81.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.96 | |||||
| 9-Day RSI | 15.28 | |||||
| 14-Day RSI | 16.96 | |||||
| 3-1 Month Momentum % | -28.07 | |||||
| 6-1 Month Momentum % | -15.75 | |||||
| 12-1 Month Momentum % | -60.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.37 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 0.55 | |||||
| Days Sales Outstanding | 188.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.4 | |||||
| Shareholder Yield % | -0.5 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -185.77 | |||||
| Net Margin % | -176.89 | |||||
| FCF Margin % | -116.56 | |||||
| ROE % | -93.46 | |||||
| ROA % | -56.68 | |||||
| ROIC % | -128.34 | |||||
| 3-Year ROIIC % | -111.86 | |||||
| ROC (Joel Greenblatt) % | -828.83 | |||||
| ROCE % | -90.14 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.72 | |||||
| PB Ratio | 2.62 | |||||
| Price-to-Tangible-Book | 7.69 | |||||
| EV-to-EBIT | -1.58 | |||||
| EV-to-EBITDA | -1.66 | |||||
| EV-to-Forward-EBITDA | -2.74 | |||||
| EV-to-Revenue | 2.88 | |||||
| EV-to-Forward-Revenue | 1.85 | |||||
| EV-to-FCF | -2.49 | |||||
| Price-to-GF-Value | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 10.25 | |||||
| Earnings Yield (Greenblatt) % | -63.09 | |||||
| FCF Yield % | -34.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arecor Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.729 | ||
| EPS (TTM) (€) | -0.328 | ||
| Beta | -0.69 | ||
| 3-Year Sharpe Ratio | -1.29 | ||
| 3-Year Sortino Ratio | -1.37 | ||
| Volatility % | 51.97 | ||
| 14-Day RSI | 16.96 | ||
| 14-Day ATR (€) | 0.002009 | ||
| 20-Day SMA (€) | 0.615 | ||
| 12-1 Month Momentum % | -60.32 | ||
| 52-Week Range (€) | 0.61 - 1.82 | ||
| Shares Outstanding (Mil) | 37.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arecor Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arecor Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arecor Therapeutics PLC Frequently Asked Questions
What is Arecor Therapeutics PLC(FRA:6UI)'s stock price today?
The current price of FRA:6UI is €0.62. The 52 week high of FRA:6UI is €1.82 and 52 week low is €0.61.
When is next earnings date of Arecor Therapeutics PLC(FRA:6UI)?
The next earnings date of Arecor Therapeutics PLC(FRA:6UI) is 2025-04-30 Est..
Does Arecor Therapeutics PLC(FRA:6UI) pay dividends? If so, how much?
Arecor Therapeutics PLC(FRA:6UI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers